Bridging the translational gap in clinical nanomedicine: From rational design to clinical reality

Abstract

Nanotechnology has demonstrated transformative potential across molecular diagnostics, targeted drug delivery, and vaccine development; yet the majority of nanoparticle systems that show promise in preclinical settings fail to achieve clinical approval, a translational attrition rate that reflects systematic design gaps rather than scientific inadequacy. This review critically examines those gaps, arguing that rational, translationally informed nanoparticle design, integrating physicochemical precision with realistic biological barrier modeling and regulatory‐grade safety characterization, is the primary determinant of clinical success. In diagnostics, we show that rationally engineered nanostructures exploiting localized surface plasmon resonance, quantum confinement, and plasmonic signal amplification do not merely enhance imaging or biosensing sensitivity in isolation, they do so through mechanisms directly applicable to overcoming the same biological barriers that limit therapeutic delivery. This mechanistic continuity between diagnostic and therapeutic design is a central theme of this review: the same surface engineering principles that prolong nanoparticle circulation for imaging determine pharmacokinetic profiles for drug delivery, and the same targeting ligands that direct contrast agents to tumors govern the efficacy of nanocarrier‐mediated chemotherapy. We leverage this shared design logic to analyze how functionalized, stimuli‐responsive nanocarriers have reshaped treatment in oncology, neurological disorders, and infectious disease, and how lipid nanoparticle platforms have redefined vaccine development, most dramatically through the clinical validation of mRNA‐LNP technology. We further introduce a dedicated perspective on AI‐enabled nanomedicine design, analyze three landmark clinical translation failures for their rational design lessons, and propose a mechanistically grounded five‐barrier translational roadmap for 2025–2035. Addressing persistent challenges in long‐term biosafety, scalable manufacturing, and regulatory standardization, this work provides both the conceptual framework and the actionable design principles needed to establish nanomedicine as a cornerstone of precision healthcare.